News & Updates

Faricimab vs aflibercept for DME in BCVA 20/50 or worse: Reduced retinal thickness, fewer jabs

05 Nov 2024

In the treatment of diabetic macular edema (DME) in the subgroup of patients with baseline best-corrected visual acuity (BCVA) of 20/50 or worse, the bispecific antibody faricimab has been shown to improve visual acuity as much as the anti-VEGF aflibercept, with the added advantage of a greater decrease in retinal thickness and reduced injection frequency.

Faricimab vs aflibercept for DME in BCVA 20/50 or worse: Reduced retinal thickness, fewer jabs

05 Nov 2024

Electrolyte abnormalities may increase mortality in patients with eating disorders

05 Nov 2024 by

Electrolyte abnormalities within 1 year of eating disorder diagnosis are associated with an increased risk of all-cause mortality, a population-based study in Canada has shown.

Electrolyte abnormalities may increase mortality in patients with eating disorders

05 Nov 2024

Data support abrocitinib use beyond 2 years in adolescents with AD

05 Nov 2024 by

Treating adolescents with moderate-to-severe AD with the JAK1-selective inhibitor abrocitinib has demonstrated an acceptable long-term safety profile and maintained efficacy for up to 112 weeks, as shown in an adolescent-focused post hoc analysis of 5 phase III trials

Data support abrocitinib use beyond 2 years in adolescents with AD

05 Nov 2024

More than 90 percent of HK’s population has CKM syndrome

05 Nov 2024 by

The proportion of Hong Kong’s population with cardiovascular-kidney-metabolic (CKM) syndrome has increased from 87.8 percent 20 years ago to 90.8 percent in 2024, an ongoing population-based, cross-sectional study of cardiovascular (CV) risk factors and disease prevalence in Hong Kong Chinese (N-CRISPS) has found.

More than 90 percent of HK’s population has CKM syndrome

05 Nov 2024

Familial hypercholesterolaemia patients with obesity face higher diabetes risk

04 Nov 2024

Patients with heterozygous familial hypercholesterolaemia do not appear to be protected against type 2 diabetes (T2D), which markedly increases in the presence of obesity, according to a worldwide cross-sectional study.

Familial hypercholesterolaemia patients with obesity face higher diabetes risk

04 Nov 2024

3 cycles of chemo enough for high-risk retinoblastoma in children

04 Nov 2024 by

Shortening the postenucleation chemotherapy regimen containing carboplatin, etoposide, and vincristine (CEV) from six to three cycles results in comparable survival outcomes in paediatric patients with unilateral pathologic high-risk retinoblastoma, according to new research.

3 cycles of chemo enough for high-risk retinoblastoma in children

04 Nov 2024

Which factors predict persistent SAB in children?

04 Nov 2024

A shorter time to culture positivity, osteoarticular infection, and higher presenting and peak values for some inflammatory markers appear predictive of persistent S. aureus bacteremia (SAB) in children, suggests a study.

Which factors predict persistent SAB in children?

04 Nov 2024

Does paternal metformin use raise risk of congenital malformation in offspring?

04 Nov 2024 by

Fathers who use metformin during the period of sperm development does not seem to contribute to congenital malformations in their children, a study has shown.

Does paternal metformin use raise risk of congenital malformation in offspring?

04 Nov 2024

Opioid does little to ease pain in aSAH-related headache

04 Nov 2024

Use of opioids results in small reductions in pain among adult patients with an aneurysmal subarachnoid haemorrhage (aSAH)-related headache, and higher doses do not appear to significantly boost its efficacy in relieving pain, according to a study.

Opioid does little to ease pain in aSAH-related headache

04 Nov 2024

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

04 Nov 2024

In this article, Professor Tam discusses her management approach to optimising outcomes in patients with inflammatory arthritis. She explores the role of the treat-to-target approach, emphasizes the importance of early disease control in reducing cardiovascular risk and evaluates the benefit-risk analysis of upadacitinib.

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

04 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

Faricimab vs aflibercept for DME in BCVA 20/50 or worse: Reduced retinal thickness, fewer jabs

Faricimab vs aflibercept for DME in BCVA 20/50 or worse: Reduced retinal thickness, fewer jabs

Electrolyte abnormalities may increase mortality in patients with eating disorders

Electrolyte abnormalities may increase mortality in patients with eating disorders

Data support abrocitinib use beyond 2 years in adolescents with AD

Data support abrocitinib use beyond 2 years in adolescents with AD

More than 90 percent of HK’s population has CKM syndrome

More than 90 percent of HK’s population has CKM syndrome

Familial hypercholesterolaemia patients with obesity face higher diabetes risk

Familial hypercholesterolaemia patients with obesity face higher diabetes risk

3 cycles of chemo enough for high-risk retinoblastoma in children

3 cycles of chemo enough for high-risk retinoblastoma in children

Which factors predict persistent SAB in children?

Which factors predict persistent SAB in children?

Does paternal metformin use raise risk of congenital malformation in offspring?

Does paternal metformin use raise risk of congenital malformation in offspring?

Opioid does little to ease pain in aSAH-related headache

Opioid does little to ease pain in aSAH-related headache

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib